{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(9)"],"submitter":["Francis SM"],"pubmed_abstract":["The high rates of recurrence and low median survival in many B-cell cancers highlight a need for new targeted therapeutic modalities. In dividing cells, eukaryotic translation initiation factor 5A (eIF5A) is hypusinated and involved in regulation of protein synthesis and proliferation, whereas the non-hypusinated form of eIF5A is a potent inducer of cell death in malignant cells. Here, we demonstrate the potential of modulating eIF5A expression as a novel approach to treating B-cell cancers. SNS01-T is a nonviral polyethylenimine-based nanoparticle, designed to induce apoptosis selectively in B-cell cancers by small interfering RNA-mediated suppression of hypusinated eIF5A and plasmid-based overexpression of a non-hypusinable eIF5A mutant. In this study, we show that SNS01-T is preferentia"],"journal":["Molecular therapy : the journal of the American Society of Gene Therapy"],"pagination":["1643-52"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4435495"],"repository":["biostudies-literature"],"pubmed_title":["SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide."],"pmcid":["PMC4435495"],"pubmed_authors":["Liu Z","Dondero R","Thompson JE","Zheng Q","Tang T","Francis SM","Taylor CA"],"additional_accession":[]},"is_claimable":false,"name":"SNS01-T modulation of eIF5A inhibits B-cell cancer progression and synergizes with bortezomib and lenalidomide.","description":"The high rates of recurrence and low median survival in many B-cell cancers highlight a need for new targeted therapeutic modalities. In dividing cells, eukaryotic translation initiation factor 5A (eIF5A) is hypusinated and involved in regulation of protein synthesis and proliferation, whereas the non-hypusinated form of eIF5A is a potent inducer of cell death in malignant cells. Here, we demonstrate the potential of modulating eIF5A expression as a novel approach to treating B-cell cancers. SNS01-T is a nonviral polyethylenimine-based nanoparticle, designed to induce apoptosis selectively in B-cell cancers by small interfering RNA-mediated suppression of hypusinated eIF5A and plasmid-based overexpression of a non-hypusinable eIF5A mutant. In this study, we show that SNS01-T is preferentia","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Sep","modification":"2026-05-01T18:20:10.397Z","creation":"2019-03-27T01:51:47Z"},"accession":"S-EPMC4435495","cross_references":{"pubmed":["24569836"],"doi":["10.1038/mt.2014.24"]}}